Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Total debt
Charles River Laboratories International, Inc.'s total debt at the end of fiscal 2025 was $2.1B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $2.6B. Over the past ten years it has ranged from $863.0M (fiscal 2015) to $2.7B (fiscal 2022); the current reading is higher than 64% of that period. Charles River Laboratories International, Inc. ranks 10th of 50 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $2.1B | (4.64%) |
| FY2024 | $2.2B | (15.37%) |
| FY2023 | $2.6B | (2.23%) |
| FY2022 | $2.7B | 1.65% |
| FY2021 | $2.7B | 34.54% |
| FY2020 | $2.0B | 4.85% |
| FY2019 | $1.9B | 13.20% |
| FY2018 | $1.7B | 45.66% |
| FY2017 | $1.1B | (7.28%) |
| FY2016 | $1.2B | 43.10% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $2.6B | (1.62%) |
| Mar 2026 | $2.7B | 24.66% |
| Dec 2025 | $2.1B | (2.25%) |
| Sep 2025 | $2.2B | (6.30%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| LH Labcorp Holdings Inc. compare | $5.9B |
| DGX Quest Diagnostics Incorporated compare | $5.6B |
| ICLR ICON PLC compare | $3.4B |
| RVTY Revvity Inc. compare | $3.2B |
| CRL Charles River Laboratories International, Inc. | $2.6B |
| QGEN QIAGEN N.V. compare | $1.6B |
| GH Guardant Health, Inc. compare | $1.5B |
| MEDP Medpace Holdings, Inc. compare | $163.0M |
| TWST Twist Bioscience Corporation compare | $15.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement